As of 2024-12-15, the Intrinsic Value of Talis Biomedical Corp (TLIS) is
1.52 USD. This TLIS valuation is based on the model Discounted Cash Flows (EBITDA Exit 5Y).
With the current market price of 4.38 USD, the upside of Talis Biomedical Corp is
-65.20%.
The range of the Intrinsic Value is 1.89 - 1.17 USD
TLIS Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(42.66) - 1.01 |
(2.15) |
-149.1% |
| DCF (Growth 10y) |
0.63 - (43.83) |
(2.60) |
-159.3% |
| DCF (EBITDA 5y) |
1.89 - 1.17 |
1.52 |
-65.2% |
| DCF (EBITDA 10y) |
1.52 - 0.59 |
1.06 |
-75.7% |
| Fair Value |
-20.62 - -20.62 |
-20.62 |
-570.86% |
| P/E |
(115.57) - (137.52) |
(135.81) |
-3200.6% |
| EV/EBITDA |
(52.86) - 5.22 |
(26.89) |
-713.9% |
| EPV |
(113.19) - (148.52) |
(130.86) |
-3087.7% |
| DDM - Stable |
(50.13) - (278.00) |
(164.07) |
-3845.9% |
| DDM - Multi |
(1.84) - (8.17) |
(3.03) |
-169.3% |
TLIS Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
54.18 |
| Beta |
2.37 |
| Outstanding shares (mil) |
12.37 |
| Enterprise Value (mil) |
-5.68 |
| Market risk premium |
4.60% |
| Cost of Equity |
7.31% |
| Cost of Debt |
5.00% |
| WACC |
5.49% |